ONO-7807
- Generic Name
- ONO-7807
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Phase 1
Terminated
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 92
- Registration Number
- NCT03446040
- Locations
- 🇺🇸
Local Institution - 0012, Lebanon, New Hampshire, United States
🇺🇸Local Institution - 0007, Aurora, Colorado, United States
🇺🇸Local Institution - 0016, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath